Assessing the risk of T-cell malignancies in mouse models of SCID-X1

Affiliations

Comment

Brian Sorrentino. Mol Ther. 2010 May.

. 2010 May;18(5):868-70.

doi: 10.1038/mt.2010.69.

¹ Division of Experimental Hematology, Department of Hematology, St Jude Children's Hospital, Memphis, Tennessee 38105, USA.

No abstract available

Comment on

Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL, Liao SH, Dane AP, Hu M, Hyman J, Finnie JW, Zheng M, Cavazzana-Calvo M, Alexander SI, Thrasher AJ, Alexander IE. Ginn SL, et al. Mol Ther. 2010 May;18(5):965-76. doi: 10.1038/mt.2010.50. Epub 2010 Mar 30. Mol Ther. 2010. PMID: 20354504 Free PMC article.
Lentiviral vector gene therapy: effective and safe?
Persons DA. Persons DA. Mol Ther. 2010 May;18(5):861-2. doi: 10.1038/mt.2010.70. Mol Ther. 2010. PMID: 20436489 Free PMC article. No abstract available.

1. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–655. - PubMed
1. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–1193. - PubMed
1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [see comments] Science. 2000;288:669–672. - PubMed
1. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181–2187. - PubMed
1. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447–458. - PubMed